Amadeus Capital Partners has hired Edward Kliphuis, who has left his role as investment director at Merck Group subsidiary M Ventures.

Small molecule drug developer C4 has fied for a $100m initial public offering, three months after the Dana-Farber Cancer Institute spinout raised a $170m round.

Kraft Group, Roche and Novartis are in line for exits after small molecule drug developer C4 filed for a $100m offering,

The MSU cancer drug spinout has been acquired on the strength of its expertise in proteasome inhibitors and preclinical pipeline.

Exosome therapy developer Codiak Biosciences – based on research at Gothenburg and MD Anderson Cancer Center – has filed to raise up to $100m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Alexandria Real Estate Equities-backed exosome therapy developer Codiak Biosciences has filed to raise up to $100m having pulled back from an earlier offering last year.

Alexandria Venture Investments contributed to a $91.5m round for Korro, which is working on RNA therapies for liver, eye and central nervous system diseases.

Optum Ventures returned to help the patient engagement platform developer close a round that came just two months after its last funding.